Home › Companies › Arcus Biosciences, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 10, 2025: 6 items on Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025: 6 passed (calculated).
Notable dissent: 2 directors (19.9%, 17.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Yasunori Kaneko, M.D. | 86,171,508 | -- | -- | 4,142,191 | 8,580,999 | 95% | Passed (calculated) | — |
| Elect Director: Patrick Machado, J.D. | 72,358,392 | -- | -- | 17,955,307 | 8,580,999 | 80% | Passed (calculated) | — |
| Elect Director: Andrew Perlman, M.D., Ph.D | 84,672,810 | -- | -- | 5,640,889 | 8,580,999 | 94% | Passed (calculated) | — |
| Elect Director: Antoni Ribas, M.D., Ph.D. | 74,827,393 | -- | -- | 15,486,306 | 8,580,999 | 83% | Passed (calculated) | — |
| 2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 | 96,750,327 | 1,952,359 | 192,012 | -- | -- | 98% | Passed (calculated) | — |
| 3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 84,812,809 | 5,446,383 | 54,507 | -- | 8,580,999 | 94% | Passed (calculated) | — |
Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
211 asset managers disclosed a vote on at least one Arcus Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Andrew Perlman, M.D., Ph.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Andrew Perlman, M.D., Ph.D”): 84,672,810 for, 5,640,889 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 23,481,581 for, 1,163,656 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,971 | 0 | 11 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,371 | 0 | 0 | 527 | For |
| Dimensional | 0 | 0 | 0 | 993,030 | Withhold |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 88,160 | 0 | 0 | 58,500 | Mixed |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 115,043 | 0 | 0 | 20,859 | Mixed |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 60,673 | 0 | 0 | 14,180 | Mixed |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,300 | 0 | 0 | 7,101 | Mixed |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Antoni Ribas, M.D., Ph.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Antoni Ribas, M.D., Ph.D.”): 74,827,393 for, 15,486,306 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 20,707,914 for, 3,937,313 withheld, 21 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,961 | 0 | 21 | 0 | For |
| Fidelity | 5,677,425 | 0 | 0 | 5,231 | For |
| State Street | 3,309 | 0 | 0 | 1,272,589 | Withhold |
| Dimensional | 0 | 0 | 0 | 993,030 | Withhold |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Victory Capital | 0 | 0 | 0 | 169,107 | Withhold |
| Equitable | 88,160 | 0 | 0 | 58,500 | Mixed |
| Columbia Threadneedle | 0 | 0 | 0 | 142,961 | Withhold |
| Jackson National | 115,043 | 0 | 0 | 20,859 | Mixed |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 105,381 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 78,952 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 77,040 | Withhold |
| Prudential/PGIM | 60,673 | 0 | 0 | 14,180 | Mixed |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 65,361 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 59,317 | Withhold |
| Empower | 0 | 0 | 0 | 53,707 | Withhold |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 0 | 49,429 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 47,401 | Withhold |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Patrick Machado, J.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Patrick Machado, J.D.”): 72,358,392 for, 17,955,307 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 20,023,416 for, 4,621,809 withheld, 23 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,436,892 | 0 | 0 | 405,967 | Mixed |
| Vanguard | 6,558,120 | 0 | 23 | 3,838 | For |
| Fidelity | 5,667,675 | 0 | 0 | 14,981 | For |
| State Street | 3,309 | 0 | 0 | 1,272,589 | Withhold |
| Dimensional | 0 | 0 | 0 | 993,030 | Withhold |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 379,100 | Withhold |
| Victory Capital | 0 | 0 | 0 | 169,107 | Withhold |
| Equitable | 88,160 | 0 | 0 | 58,500 | Mixed |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 135,902 | Withhold |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 105,381 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 78,952 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 77,040 | Withhold |
| Prudential/PGIM | 60,673 | 0 | 0 | 14,180 | Mixed |
| BNY Mellon | 0 | 0 | 0 | 71,161 | Withhold |
| Principal | 0 | 0 | 0 | 65,361 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 59,317 | Withhold |
| Empower | 0 | 0 | 0 | 53,707 | Withhold |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 0 | 0 | 0 | 49,429 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 47,401 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 46,686 | Withhold |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Yasunori Kaneko, M.D.
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Yasunori Kaneko, M.D.”): 86,171,508 for, 4,142,191 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 23,481,221 for, 1,164,020 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,561,975 | 0 | 7 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,371 | 0 | 0 | 527 | For |
| Dimensional | 0 | 0 | 0 | 993,030 | Withhold |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 88,160 | 0 | 0 | 58,500 | Mixed |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 115,043 | 0 | 0 | 20,859 | Mixed |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 60,673 | 0 | 0 | 14,180 | Mixed |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,300 | 0 | 0 | 7,101 | Mixed |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Prior year: 96.3% for (June 6, 2024 meeting) ▼ 2.3 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
Arcus Biosciences, Inc.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 84,812,809 for, 5,446,383 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,558,133 | 3,849 | 0 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,286 | 612 | 0 | 0 | For |
| Dimensional | 993,030 | 0 | 0 | 0 | For |
| Charles Schwab | 651,485 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 146,660 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 135,902 | 0 | 0 | 0 | For |
| TIAA | 0 | 129,930 | 0 | 0 | Against |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 14,180 | 60,673 | 0 | 0 | Mixed |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 49,977 | 0 | 0 | 0 | For |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,401 | 0 | 0 | 0 | For |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 24,388,198 for, 245,795 against, 11,254 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 31,424,760 | 0 | 0 | 0 | For |
| Woodline Partners LP | 6,292,618 | 0 | 0 | 0 | For |
| Fidelity | 4,421,482 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,398,503 | 0 | 0 | 0 | For |
| State Street | 2,443,134 | 22,859 | 0 | 0 | For |
| Point72 | 2,081,016 | 0 | 0 | 0 | For |
| BlackRock | 1,952,836 | 14,443 | 0 | 0 | For |
| Siren, L.L.C. | 0 | 0 | 0 | 0 | Not Voted |
| GEODE CAPITAL MANAGEMENT, LLC | 1,409,668 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,396,275 | 0 | 0 | Against |
| RA CAPITAL MANAGEMENT, L.P. | 1,029,400 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 744,301 | 0 | 0 | 0 | For |
| Charles Schwab | 741,231 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 627,626 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 503,101 | 0 | 0 | 0 | For |
| Wellington | 472,544 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 384,924 | 0 | 0 | 0 | For |
| Northern Trust | 382,230 | 459 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 379,100 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 336,085 | 0 | 0 | 0 | For |
| Granahan Investment Management, LLC | 308,320 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 281,869 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 255,064 | 0 | 0 | Against |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 231,608 | 0 | 0 | Against |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 229,124 | 0 | 0 | 0 | For |
Institutional-manager reports, all 165 managers: 62,603,305 for, 3,032,532 against, 575 abstained, 1,612,077 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.5% for (June 6, 2024 meeting) ▼ 0.5 pts
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.
Arcus Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 96,750,327 for, 1,952,359 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 23,821,968 for, 812,026 against, 11,254 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,842,859 | 0 | 0 | 0 | For |
| Vanguard | 6,558,140 | 3,842 | 0 | 0 | For |
| Fidelity | 5,682,656 | 0 | 0 | 0 | For |
| State Street | 1,275,813 | 85 | 0 | 0 | For |
| Dimensional | 993,030 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 651,485 | 0 | 0 | Against |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Victory Capital | 169,107 | 0 | 0 | 0 | For |
| Equitable | 146,660 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 142,961 | 0 | 0 | 0 | For |
| Jackson National | 135,902 | 0 | 0 | 0 | For |
| TIAA | 129,930 | 0 | 0 | 0 | For |
| American Century | 105,381 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 95,512 | 0 | 0 | 0 | For |
| MFS | 78,952 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 77,040 | 0 | 0 | 0 | For |
| Prudential/PGIM | 74,853 | 0 | 0 | 0 | For |
| BNY Mellon | 71,161 | 0 | 0 | 0 | For |
| Principal | 65,361 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 59,317 | 0 | 0 | 0 | For |
| Empower | 53,707 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 49,977 | 0 | 0 | Against |
| Thrivent | 49,429 | 0 | 0 | 0 | For |
| Lincoln Financial | 47,401 | 0 | 0 | 0 | For |
| Goldman Sachs | 46,686 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 105,900,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 6.46% |
| 2 | Vanguard | 6.20% |
| 3 | Fidelity | 5.37% |
| 4 | State Street | 1.20% |
| 5 | Dimensional | 0.94% |
| 6 | Charles Schwab | 0.62% |
| 7 | Delaware/Macquarie | 0.36% |
| 8 | Victory Capital | 0.16% |
| 9 | Equitable | 0.14% |
| 10 | Columbia Threadneedle | 0.13% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 29.67% |
| 2 | Woodline Partners LP | 5.94% |
| 3 | Fidelity | 4.18% |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 3.21% |
| 5 | State Street | 2.33% |
| 6 | Point72 | 1.97% |
| 7 | BlackRock | 1.86% |
| 8 | Siren, L.L.C. | 1.52% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.33% |
| 10 | BNP Paribas Asset Management Holding S.A. | 1.32% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 31,424,760 | 29.67% | Schedule 13D, filed November 5, 2025 |
| BlackRock, Inc. | 12,736,927 | 12.03% | Schedule 13G, filed January 8, 2026 |
| The Vanguard Group, Inc. | 6,161,943 | 5.82% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| FMR (Fidelity) | 4,456,846 | 4.21% | Form 13F, quarter ended March 31, 2025 |
| State Street | 3,696,479 | 3.49% | Form 13F, quarter ended March 31, 2025 |
| Terry Rosen, Ph.D. | 2,571,357 | 2.43% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Dimensional Fund Advisors | 1,722,083 | 1.63% | Form 13F, quarter ended March 31, 2025 |
| Juan Carlos Jaen, Ph.D. | 1,444,741 | 1.36% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Geode Capital | 1,389,232 | 1.31% | Form 13F, quarter ended March 31, 2025 |
| Wellington Management | 1,082,808 | 1.02% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 105,900,000 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Arcus Biosciences, Inc.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 211 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,629 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Arcus Biosciences (RCUS) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.